Vertex targets H2 2026 for first VX-670 muscle-biopsy data in DM1
The GALILEO trial's multiple-ascending-dose cohort will report safety, tolerability, and a muscle splicing-index readout, the first clinical signal for Vertex's small-molecule bet on myotonic dystrophy type 1.
Executive Summary
- Vertex is heading toward its first disclosed clinical data for VX-670, a candidate testing a modality with no other active competitor in myotonic dystrophy type 1.
- The primary measure is safety and tolerability, with muscle-biopsy and pharmacokinetic readouts as secondary measures, so the readout will inform tolerability and target engagement rather than deliver a proof of efficacy.
- The trial's completion date has moved out even as enrollment grew, a pattern consistent with dosing more participants ahead of a partial, interim data disclosure rather than a full-trial delay.
- The field is active but mechanistically split between RNA-targeted and gene-therapy approaches, leaving VX-670 without a direct same-modality comparator to benchmark against.
The catalyst
Vertex said it is on track to complete enrollment and dosing in the multiple-ascending-dose (MAD) portion of the GALILEO Phase 1/2 study of VX-670 and to share results in the second half of 2026. The trial, registered as NCT06185764, is testing VX-670 in adults with myotonic dystrophy type 1 (DM1) across ten countries including the United States, Canada, and the United Kingdom. The registered primary endpoint is safety and tolerability, measured by the number of participants with adverse events across the trial's Part A and Part B cohorts. Secondary endpoints include pharmacokinetic exposure (AUC, Cmax) and change in splicing index in muscle biopsy, a molecular measure of the drug's effect on DM1-associated mis-splicing. Vertex+1Vertex Reports First Quarter 2026 Financial ResultsMay 4, 2026A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)NCT06185764
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial context and timing
The trial's enrollment target rose from 36 to 44 in February 2026 and then to 52 in June 2026, while the primary completion date moved from December 22, 2026 to February 2, 2027 over the same period. The enrollment increase reflects routine adjustment within an early-phase design, and the operational risk model does not flag it as a deviation. The gap between the guided H2 2026 readout window and the registry's February 2027 primary completion date indicates that the disclosed results will come from an interim MAD cohort analysis, not the trial's full completion. NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)NCT06185764
What the readout can establish
As a Phase 1/2 safety and dose-finding study, the trial is built to test whether ascending doses of VX-670 are tolerated and whether the drug reaches muscle tissue and shifts the splicing index, the molecular signature of DM1 pathology. It is not designed to establish a clinical efficacy claim on its own. The trial is randomized against a placebo comparator, giving the MAD portion a controlled basis for interpreting any early pharmacodynamic signal. NCT06185764A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)NCT06185764
Competitive frame
The DM1 clinical field includes competing programs from Dyne Therapeutics (DYNE-101, targeting DMPK RNA), Avidity Biosciences (delpacibart etedesiran, now in Phase 3), Sanofi (SAR446268, an AAV gene therapy), ARTHEx Biotech (ATX-01, targeting miR-23b), and PepGen (PGN-EDODM1). All of these are oligonucleotide, RNA-targeted, or gene-therapy approaches; VX-670 is registered as a small molecule, the only small-molecule program listed as active in this indication. That leaves VX-670 without a same-modality comparator among current DM1 programs, so the trial's early data will be read on its own tolerability and pharmacodynamic terms rather than against a matched precedent.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.